DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

Search

Ocugen Inc

Fechado

1.78 1.71

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.76

Máximo

1.87

Indicadores-chave

By Trading Economics

Rendimento

611K

-15M

Vendas

-108K

1.4M

Margem de lucro

-1,073.489

Funcionários

95

EBITDA

724K

-13M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+367.03% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

250M

568M

Abertura anterior

0.07

Fecho anterior

1.78

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Ocugen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de out. de 2025, 20:45 UTC

Ganhos

Costco Wholesale Sales Climb in September, Early October

8 de out. de 2025, 20:12 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 de out. de 2025, 16:39 UTC

Grandes Movimentos do Mercado

Mining Shares Rise as Gold Prices Soar

8 de out. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

8 de out. de 2025, 23:43 UTC

Conversa de Mercado

Gold Falls on Possible Profit-Taking -- Market Talk

8 de out. de 2025, 23:18 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Finance Acquisition Using Internal Funds

8 de out. de 2025, 23:17 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 de out. de 2025, 23:16 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 de out. de 2025, 21:54 UTC

Conversa de Mercado
Ganhos

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 de out. de 2025, 21:30 UTC

Conversa de Mercado

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 de out. de 2025, 21:26 UTC

Conversa de Mercado
Ganhos

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de out. de 2025, 19:15 UTC

Conversa de Mercado

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 de out. de 2025, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 de out. de 2025, 18:47 UTC

Conversa de Mercado

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Will Remain a Publicly Traded Co >TASK

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 de out. de 2025, 18:07 UTC

Conversa de Mercado

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 de out. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

8 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de out. de 2025, 15:57 UTC

Conversa de Mercado

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 de out. de 2025, 15:56 UTC

Conversa de Mercado

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 de out. de 2025, 15:53 UTC

Conversa de Mercado

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 de out. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 de out. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 de out. de 2025, 15:43 UTC

Aquisições, Fusões, Aquisições de Empresas

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 de out. de 2025, 15:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparação entre Pares

Variação de preço

Ocugen Inc Previsão

Preço-alvo

By TipRanks

367.03% parte superior

Previsão para 12 meses

Média 8.5 USD  367.03%

Máximo 15 USD

Mínimo 4 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Ocugen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.6818 / 0.74Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat